Peptides
Retatrutide
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist studied in metabolic research. Below, we compare vendors currently stocking research-grade Retatrutide — not just a single sales page.
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist studied in metabolic research. Below, we compare vendors currently stocking research-grade Retatrutide — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 Amino VaultBest Value |
$102.00 – $289.00 (AminoGLP-3 RT) | Third-party COA | Buy Here → | |
 Purity Peptides |
$104.99 – $299.99 | Third-party COA | Buy Here → | |
 American Peptides |
From $105.00 | Third-party COA | Buy Here → | |
 Next Chem |
$120.00 – $259.95 | Third-party COA | Auto-applied | Buy Here → |
Retatrutide is a synthetic peptide developed by Eli Lilly that acts as a triple agonist at GLP-1, GIP, and glucagon receptors simultaneously — a novel mechanism among incretin-based compounds that has generated substantial research and media interest in metabolic and obesity research.
Research-grade Retatrutide is typically supplied as a lyophilized powder in sealed vials, commonly at 5mg to 30mg strengths, intended for laboratory research use; it has been studied clinically as an investigational drug and, as of this writing, is not FDA-approved for any marketed indication.
By simultaneously activating three distinct incretin-family receptors — GLP-1, GIP, and glucagon receptors — Retatrutide is studied for combining appetite suppression (GLP-1/GIP) with increased energy expenditure via the glucagon receptor, a combination researchers have proposed may produce greater metabolic effects than single- or dual-agonist compounds.
Published Phase 2 clinical trial data has shown substantial body-weight reduction in trial participants, making Retatrutide one of the most closely watched investigational compounds in obesity-pharmacology research.
Beyond weight outcomes, researchers have studied Retatrutide's triple-agonist mechanism for its effects on markers of liver fat, blood glucose, and lipid metabolism in trial populations.
Published clinical trial data for Retatrutide has reported gastrointestinal side effects (nausea, diarrhea, vomiting) consistent with other incretin-receptor agonists, along with the trial-specific safety monitoring associated with an investigational drug; it is not FDA-approved, and research-grade material sourced outside Eli Lilly's regulated trial supply chain has not undergone the same quality controls.
Doses used in published Phase 2 clinical trials are documented in that trial literature and are specific to those regulated study protocols; no FDA-approved commercial dosage exists for Retatrutide research material.
Compound X does not sell Retatrutide directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
Retatrutide clinical trial data is indexed on PubMed and ClinicalTrials.gov under "Retatrutide triple agonist obesity trial."
New guides, vendor comparisons and compound breakdowns every week.